Jessica Garner
Psychiatric/Mental Health · Price, UTNPI 1457093502
Payments from drug & device makers
Across 31 payments — averaging $20.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$377
- Alkermes, Inc.$95
- UCB, Inc.$44
- Supernus Pharmaceuticals, Inc.$41
- Braeburn Inc.$31
- Neurocrine Biosciences, Inc.$24
- plus $19 from 1 others
What the payments were for
- Food & beverage$631100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 20 | $377 |
| Alkermes, Inc. | 4 | $95 |
| UCB, Inc. | 2 | $44 |
| Supernus Pharmaceuticals, Inc. | 1 | $41 |
| Braeburn Inc. | 2 | $31 |
| Neurocrine Biosciences, Inc. | 1 | $24 |
| Axsome Therapeutics, Inc. | 1 | $19 |
How this compares
$631 in reported general payments places this provider in the 50th percentile of 393 psychiatric/mental health providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AuvelityDextromethorphan Hbr/Bupropion | 11 | $14,207 |
| VraylarCariprazine Hcl | 11 | $13,909 |
| MounjaroTirzepatide | 11 | $11,569 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 22 | $2,104 |
| Bupropion XlBupropion Hcl | 25 | $1,420 |
| Lamotrigine | 46 | $647 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 14 | $500 |
| Omeprazole | 21 | $296 |
| Pregabalin | 13 | $225 |
| Quetiapine Fumarate | 27 | $212 |
| Paroxetine Hcl | 27 | $211 |
| Levothyroxine Sodium | 24 | $154 |
| Trazodone Hcl | 21 | $149 |
| Buspirone Hcl | 29 | $139 |
| Ropinirole Hcl | 11 | $135 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Axsome Therapeutics, Inc.Auvelity | $19 | $14,20711 claims |
| AbbVieVraylar | $377 | $13,90911 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 393 psychiatric/mental health providers in Utah.
Other psychiatric/mental health in Price
- Bret HafenLayton$381K
- Alberto SouzaSaint George$114K
- Anthony BrowningOrem$32K
- Debra HainRiverton$29K
- Kristin BarberSalt Lake City$28K
- Briana TerrySalt Lake City$14K
- Paige MarshallSaint George$13K
- Derick MoodySpringville$8K
- Sumer AndersonSandy$8K
- Colby JamesLayton$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.